📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-04 17:23
635 analysed today
635
Today
133,524
All-time analysed
40,118
Positive
6,284
Negative
79,305
Neutral
7,749
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
51 announcements match the current filters (relevance ≥ 5).
Mukka Proteins Obtains EU Organic Attestation from ECOCERT France Valid Till March 2028
Mukka Proteins Limited has received an EU – Inputs Attestation from ECOCERT S.A.S., France, confirming that its product 'Eco Sphere Organic Fertilizer' is suitable for use in organic farming. The attestation is issued under EU Regulations (EU) No. 2018/848 and No. 2021/1165. The approval is valid from September 4, 2026 until March 31, 2028. This certification enables the company to market its value-added organic fertilizer product across European Union organic farming markets.
Confidence: HIGH
What changedMukka Proteins received ECOCERT attestation qualifying its Eco Sphere Organic Fertilizer for use in organic farming across the European Union.
Why it mattersEnables Mukka Proteins to expand from core fish meal and fish oil commodities into higher-margin, value-added organic fertilizer exports in European markets.
Attestation validity start date: September 4, 2026Attestation validity end date: March 31, 2028Applicable EU Regulations: No. 2018/848 and No. 2021/1165Revenue impact: not disclosed
📅 Short termPositive for sentiment as it validates product quality standards, but immediate financial impact is not quantified in the filing.
📈 Long termProvides regulatory clearance to enter European organic agriculture supply chains, supporting long-term product diversification and export margin improvement.
⚠ Risk flags
- Commercial order sizes and pricing realizations in EU markets are yet to be established
Key Highlights
Received EU – Inputs Attestation from ECOCERT S.A.S., France, for 'Eco Sphere Organic Fertilizer'
Complies with Regulations (EU) No. 2018/848 and No. 2021/1165 for organic farming inputs
Approval validity period: September 4, 2026 to March 31, 2028
Aims to expand the company's value-added and sustainable product offerings in international markets
👀 What to Watch
Track whether this certification translates into commercial export orders or distribution agreements in the EU for value-added organic fertilizers in upcoming quarterly disclosures.
Mukka Proteins to Acquire 16.77% Stake in Shipwaves Online for Rs 13.19 Cr
Mukka Proteins has approved a strategic minority investment of up to Rs 13.19 Cr in Shipwaves Online Limited (SOL) to acquire a 16.77% stake. SOL operates in digital freight forwarding and enterprise SaaS solutions, posting FY26 turnover of Rs 65.01 Cr and PAT of Rs 1.68 Cr. The transaction is structured as a related party transaction at arm's length (cash consideration of Rs 4.50 per share) and is slated to complete by March 31, 2027.
Confidence: HIGH
What changedMukka Proteins' Board approved acquiring a 16.77% minority stake in logistics SaaS provider Shipwaves Online Limited for Rs 13.19 Cr.
Why it mattersThe deal aims to capture business synergies in freight forwarding and logistics, representing ~1.6% of Mukka's market cap, though it constitutes a related party transaction.
Total investment value: Rs 13,19,40,000Stake acquired: 16.77%Investment vs Market Cap: ~1.6%Target FY26 turnover: Rs 65,01,44,787Target FY26 PAT: Rs 1,68,46,716Completion date: 31-03-2027
📅 Short termLimited near-term impact on earnings given the modest deal size and tranche-based funding scheduled through March 2027.
📈 Long termMay optimize digital freight and export logistics efficiencies, though financial contribution will remain limited to minority investment returns.
⚠ Risk flags
- Related party transaction (Mukka is a Promoter Group entity of the target)
- Non-controlling minority stake (16.77%)
Key Highlights
Approved cash investment of up to Rs 13.19 Cr for 2,93,20,000 equity shares at Rs 4.50 per share
Acquisition results in a 16.77% minority stake in Shipwaves Online Limited
Target recorded FY26 turnover of Rs 65.01 Cr and PAT of Rs 1.68 Cr with a net worth of Rs 71.30 Cr
Classified as a related party transaction with an indicative completion timeline of March 31, 2027
👀 What to Watch
Track the execution of share subscription tranches through March 31, 2027, and any disclosures on operational freight synergies for Mukka's export supply chain.
Mukka Proteins plans to scale Bengaluru wet waste bioconversion to 1,000 TPD by Dec 2027
Mukka Proteins announced the operational scaling roadmap for its circular bio-economy vertical in Bengaluru using Black Soldier Fly bioconversion. The facility's organic wet waste intake is currently at 200 Tonnes Per Day (TPD), with plans to expand to 400 TPD by March 2027 and up to 1,000 TPD by December 2027. The bioconversion process delivers an 80% mass reduction in a 10-14 day cycle to produce insect protein meal (>50% crude protein), lipids, organic frass, and humic acid. This initiative diversifies the company beyond its conventional marine protein footprint of 2,91,720 MTPA.
Confidence: HIGH
What changedDetailed a phased commercial scale-up roadmap to expand municipal wet waste conversion in Bengaluru from 200 TPD to 1,000 TPD by December 2027.
Why it mattersEnables product diversification into high-value sustainable feed ingredients and bio-stimulants, helping reduce earnings volatility linked to seasonal fish catch cycles.
Current processing intake: 200 TPDTarget intake by March 2027: 400 TPDTarget intake by Dec 2027: 1,000 TPDBio-mass reduction rate: 80% in 10-14 daysExisting marine capacity: 2,91,720 MTPA
📅 Short termProvides positive strategic visibility on ESG and product diversification, though near-term financial impact at the initial 200 TPD run rate will be modest.
📈 Long termScaling to 1,000 TPD could build a non-marine animal nutrition and bio-stimulant revenue stream with carbon credit monetization opportunities.
⚠ Risk flags
- Municipal waste supply consistency and feedstock logistics risk
- Capex requirement and unit economics were not disclosed in the press release
Key Highlights
Organic wet waste intake currently at 200 TPD, targeted to reach 400 TPD by March 2027 and 1,000 TPD by December 2027
Black Soldier Fly larval process achieves 80% mass reduction of organic waste within a 10 to 14 days cycle
Produces insect protein meal with >50% crude protein along with feed-grade oil, compost, and humic acid
Complements existing marine protein manufacturing capacity of over 2,91,720 MTPA across India and Oman
👀 What to Watch
Track execution progress toward the 400 TPD processing target by March 2027 and monitor revenue/margin contribution disclosures from the insect protein vertical in upcoming quarters.
Mukka Proteins Gets NSE & BSE In-Principle Nod for Rs 47 Cr Warrant Issue
Mukka Proteins Limited has received in-principle approvals from NSE and BSE for the preferential issue of 2,00,00,000 convertible warrants. The warrants carry a face value of Re 1 and an issue price of Rs 23.50 each, totaling a capital raise of Rs 47.00 crore from non-promoters. The fundraise represents approximately 5.8% of the company's market capitalization of Rs 804 crore. The proceeds will provide growth capital ahead of the full equity conversion window.
Confidence: HIGH
What changedStock exchanges granted formal in-principle clearance for Mukka Proteins to issue 2 crore convertible warrants at Rs 23.50 each to non-promoters.
Why it mattersProvides an equity capital pipeline of Rs 47.00 crore to fund ongoing expansion and balance sheet deleveraging (current debt is Rs 682 Cr).
Warrants to be issued: 2,00,00,000Issue price per warrant: Rs. 23.50Total fundraise value: Rs 47.00 CrFundraise vs Market Cap: ~5.8%Approval Date: August 28, 2026
📅 Short termClearance allows the company to complete the allotment process and collect initial warrant subscription money.
📈 Long termSupports balance sheet strength and long-term expansion goals, though it will result in mild equity dilution upon final conversion.
⚠ Risk flags
- Equity dilution upon warrant conversion
- Dependency on full warrant exercise within regulatory timelines
Key Highlights
Received stock exchange in-principle approval from NSE and BSE on August 28, 2026.
Issuance of 2,00,00,000 convertible warrants of Re 1 face value at Rs 23.50 per warrant.
Total capital to be raised amounts to Rs 47.00 crore upon full warrant conversion.
Warrants allocated exclusively to non-promoter category investors.
👀 What to Watch
Track the formal allotment of warrants, upfront payment receipts (minimum 25%), and end-use disclosures in upcoming quarterly updates.
Mukka Proteins Targets ₹3,000 Cr Revenue by FY30; Secures ₹475 Cr Waste Management Order
Mukka Proteins has outlined a strategic roadmap to double its revenue to over ₹3,000 Cr by FY30, up from ₹1,449 Cr in FY26. The company is diversifying from its core fishmeal business (25-30% market share) into high-margin segments like insect protein (1,400 TPD capacity) and waste management. A significant milestone is the ₹474.89 Cr leachate treatment contract from Bengaluru Solid Waste Management Ltd, representing ~33% of TTM revenue. Exports continue to dominate the mix, accounting for 89.5% of Q1 FY27 revenue across 25+ countries.
Confidence: HIGH
What changedThe company has formally transitioned from a marine-focused producer to an integrated animal protein and sustainability platform with specific long-term revenue targets.
Why it mattersDiversification into waste management and insect protein reduces the business's historical reliance on cyclical marine sourcing and seasonal fishing bans while improving ESG positioning.
FY30 Revenue Target: ₹3,000+ CrLeachate Project Value: ₹474.89 CrOrder vs TTM Revenue: ~32.8%Export Revenue Share (Q1 FY27): 89.5%Insect Protein Capacity: 1,400 TPDFishmeal/Oil Capacity: 2,91,720 MT/year
📅 Short termThe market is likely to react positively to the clear growth guidance and the substantial waste management order which provides revenue visibility.
📈 Long termStructural shift toward a circular economy model (waste-to-protein) could lead to a re-rating if the company successfully scales its non-marine verticals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High Debt-to-Equity ratio of 1.53
- Execution risk in the new leachate treatment segment
- Dependence on seasonal fishing bans for core raw materials
Key Highlights
Targeting revenue of ₹3,000+ Cr by FY30, a 2x growth target over approximately 4 years.
Secured a ₹474.89 Cr order for legacy leachate treatment in Bengaluru, a major diversification into waste-to-value.
Maintains a dominant 25-30% market share in India's fish meal and fish oil revenue.
Export revenue share reached 89.5% in Q1 FY27, highlighting strong global demand.
Expanding into insect protein with a 1,400 TPD capacity and carbon credit potential.
👀 What to Watch
Watch for the execution of the Bengaluru leachate project (6-month build timeline) and the margin impact of the new Oman facility and insect protein segments.
186.7% Revenue Growth in Q1 FY27; PAT Surges to ₹18.6 Cr with Strategic M&A
Mukka Proteins reported a massive 186.7% YoY revenue growth to ₹489.65 Cr for Q1 FY27, driven by strong domestic and export demand amid global supply constraints. PAT surged 1072.5% YoY to ₹18.63 Cr, benefiting from operating leverage and a low base in the previous year. The company also announced a 51% stake acquisition in Delta Marine Products for ₹11.1 Cr and the resolution of a ₹15.24 Cr customs litigation. While EBITDA margins remained stable at 9.93%, the quarterly revenue represents approximately 33.8% of the total TTM revenue, indicating a strong start to the fiscal year.
Confidence: HIGH
What changedMukka Proteins has transitioned into a high-growth phase in Q1 FY27, supported by inorganic expansion (Delta Marine) and the removal of a significant legal liability.
Why it mattersThe results demonstrate strong operating leverage and the ability to capitalize on global supply shortages, while the M&A activity signals aggressive capacity expansion to maintain its 25-30% domestic market share.
Q1 FY27 Revenue: ₹489.65 CrQ1 FY27 PAT: ₹18.63 CrAcquisition Cost (Delta Marine): ₹11.1 CrLitigation Demand Set Aside: ₹15.24 CrRevenue vs TTM Revenue: 33.8%
📅 Short termThe stock is likely to react positively to the triple combination of exceptional earnings growth, a strategic acquisition, and a favorable legal outcome.
📈 Long termThe company is structurally expanding its footprint in the Middle East and diversifying into waste management, which could re-rate the business if execution remains consistent.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High Debt-to-Equity ratio of 1.53
- Volatility in global fish meal prices
- Seasonal fishing bans affecting raw material supply
Key Highlights
Consolidated Revenue increased 186.7% YoY to ₹489.65 Cr from ₹170.77 Cr.
PAT grew by 1072.5% YoY to ₹18.63 Cr compared to ₹1.59 Cr in Q1 FY26.
Acquired 51% stake in Delta Marine Products for ₹11.1 Cr to enhance manufacturing capacity.
Resolved a long-standing customs litigation with a demand of ₹15.24 Cr set aside by CESTAT.
EBITDA margin improved slightly by 17 bps YoY to 9.93%.
👀 What to Watch
Investors should monitor the integration of Delta Marine Products and the progress of the 68% stake acquisition in Oman-based United Gulf Fishery. Key focus should remain on whether the high revenue growth can be sustained as global fish meal prices and supply normalize.
₹75 Cr NCD Issuance Cancelled; Mukka Proteins to Acquire 25.98% Stake in Swachha Eco Solutions
Mukka Proteins has cancelled its proposed ₹75 crore Non-Convertible Debenture (NCD) issuance, which would have represented approximately 11% of its current debt. The company is diversifying its interests by investing ₹64.93 lakh for a 25.98% stake in Swachha Eco Solutions Private Limited, making it an associate company. Additionally, the board has approved the re-appointment of the core leadership team, including the MD, CFO, and COO, for five-year terms starting January 2027. While Q1 FY27 results were approved, the specific financial figures were not detailed in the primary announcement text.
Confidence: HIGH
What changedThe company has retracted its plan to raise ₹75 crore in debt and has secured its top management for the next five years while adding a new associate company in the eco-solutions space.
Why it mattersThe NCD cancellation prevents further leverage on a balance sheet that already has a D/E of 1.53. Management continuity provides stability for the company's planned expansion into Oman and product diversification.
Cancelled NCD Value: ₹75,00,00,000Investment in SESPL: ₹64,92,500Stake in SESPL: 25.98%Cancelled NCD vs Total Debt: ~11%Management Re-appointment Term: 5 years
📅 Short termThe stock may see neutral to slightly positive sentiment as the cancellation of a debt raise prevents immediate dilution of credit metrics, though the lack of Q1 figures in the summary is a wait-and-watch.
📈 Long termLeadership stability through 2032 is a positive structural signal. The small investment in Swachha Eco Solutions suggests a minor strategic pivot or ESG-related synergy.
⚠ Risk flags
- High Debt/Equity ratio of 1.53
- Related-party management (MD, CFO, and COO are brothers)
Key Highlights
Cancelled the proposed issuance of Senior Secured NCDs aggregating up to ₹75,00,00,000.
Approved a capital contribution of ₹64,92,500 to acquire a 25.98% stake in Swachha Eco Solutions Private Limited.
Re-appointed Kalandan Mohammed Haris as MD & CEO for a 5-year term starting January 20, 2027.
Re-appointed CFO and COO for 5-year terms, ensuring management continuity through 2032.
Scheduled the 16th Annual General Meeting (AGM) for September 10, 2026.
👀 What to Watch
Investors should monitor the upcoming AGM on September 10, 2026, for management's explanation regarding the NCD cancellation and the strategic intent behind the Swachha Eco Solutions investment.
₹75 Cr NCD Cancelled; Mukka Proteins Re-appoints Top Management and Invests in Associate
Mukka Proteins has cancelled its proposed ₹75 crore Non-Convertible Debenture (NCD) issuance, which represented approximately 9.5% of its market capitalization. The board approved a small strategic investment of ₹64.93 lakh to acquire a 25.98% stake in Swachha Eco Solutions Private Limited, making it an associate company. Crucially, the company secured leadership continuity by re-appointing the Managing Director, CFO, and COO for five-year terms starting January 2027. The Q1 FY27 financial results were also approved, though specific P&L figures were not detailed in the summary text.
Confidence: HIGH
What changedThe company has opted out of a significant debt fundraise and solidified its top management structure for the next five years while adding a new associate company in the eco-solutions space.
Why it mattersLeadership continuity among the promoter-directors is vital for the company's 28% growth target, while the NCD cancellation may indicate a shift in capital allocation or improved internal cash flows.
NCD Cancellation Value: ₹75,00,00,000NCD vs Market Cap: ~9.5%Investment in SESPL: ₹64,92,500Stake in SESPL: 25.98%Management Term Extension: 5 Years
📅 Short termThe stock may see neutral to slightly cautious movement as the market digests the cancellation of the NCD and waits for the full Q1 FY27 earnings breakdown.
📈 Long termManagement stability is a positive structural signal, though the high debt-to-equity ratio (1.53) remains a key metric to watch alongside the Oman acquisition progress.
⚠ Risk flags
- High management concentration (MD, CFO, and COO are brothers)
- High Debt-to-Equity ratio of 1.53
- Small-scale diversification into non-core eco-solutions
Key Highlights
Cancelled the proposed issuance of ₹75 crore Senior Secured Rated Listed NCDs.
Approved investment of ₹64,92,500 for a 25.98% stake in Swachha Eco Solutions Private Limited.
Re-appointed Kalandan Mohammed Haris (MD & CEO) and two other key directors for 5-year terms until 2032.
Scheduled the 16th Annual General Meeting (AGM) for September 10, 2026.
Confirmed the re-appointment of three Independent Directors for second 5-year terms.
👀 What to Watch
Investors should monitor the upcoming Q1 FY27 detailed financial statements to understand the impact of global fish meal price normalization and the rationale behind cancelling the ₹75 Cr debt raise.
Rs 47 Cr Fundraise: Mukka Proteins Shareholders Approve 2 Crore Convertible Warrants
Shareholders of Mukka Proteins have approved a special resolution to issue 2,00,00,000 convertible warrants to 15 non-promoter entities. The warrants are priced at Rs 23.50 each, aggregating to a total fundraise of Rs 47 crore. This represents approximately 6.1% of the company's current market capitalization. Subscribers will pay 25% of the issue price upfront (Rs 11.75 crore), with the remaining 75% payable upon conversion into equity shares within 18 months.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise Rs 47 crore through a preferential issue of warrants to non-promoter investors.
Why it mattersThe fundraise provides essential growth capital for a company with a high debt-to-equity ratio of 1.53. It supports the company's strategy to diversify its product line and expand into the Middle East market via its Oman-based acquisition.
Total Issue Size: Rs 47 CrIssue Price per Warrant: Rs 23.50Issue size vs Market Cap: ~6.1%Upfront Payment (25%): Rs 11.75 CrTotal Warrants: 2,00,00,000
📅 Short termThe approval is likely to be viewed positively as it confirms investor interest at a price (Rs 23.50) slightly above the current market price (Rs 23.40).
📈 Long termIf successfully converted and deployed, this capital could help scale operations and improve margins through diversification, though it will result in a roughly 6% equity dilution.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution of approximately 6%
- Execution risk related to the Oman acquisition
- High debt-to-equity ratio of 1.53
Key Highlights
Issuance of 2,00,00,000 convertible warrants at a fixed price of Rs 23.50 per warrant.
Total capital infusion of Rs 47 crore approved by shareholders via postal ballot.
Upfront payment of 25% (Rs 11.75 crore) required at the time of warrant subscription.
Warrants are convertible into equity shares of face value Rs 1 within a period of 18 months.
Issue is directed to 15 specific non-promoter allottees, including individuals and entities like Multiplex Capital Limited.
👀 What to Watch
Watch for the formal allotment of warrants and the subsequent inflow of the 25% upfront capital. Investors should monitor how these funds are deployed toward the company's stated goal of product diversification and the Oman acquisition.
₹15.24 Cr customs duty demand set aside by CESTAT in favor of Mukka Proteins
Mukka Proteins has received a favorable ruling from the CESTAT Bangalore Regional Bench, which set aside a customs duty demand of ₹15.24 crore. The dispute, dating back to imports from 2014-2015, involved allegations of undervaluation and misdeclaration of fish meal. The tribunal ruled that the Customs Department failed to provide cogent evidence, effectively removing a liability equivalent to approximately 26.7% of the company's TTM Net Profit (₹57 Cr). Additionally, the company is now eligible to seek a refund of ₹0.75 crore previously appropriated by authorities.
Confidence: HIGH
What changedA long-standing legal dispute regarding customs duty valuation has been resolved in favor of the company, cancelling a ₹15.24 Cr demand.
Why it mattersThe ruling prevents a significant cash outflow that would have impacted nearly 27% of the company's annual PAT, providing financial relief and clearing a regulatory overhang.
Quantified demand set aside: ₹15,24,30,536Potential refund: ₹75,00,000Demand vs TTM PAT: ~26.7%Demand vs Net Worth: ~3.4%Import period in dispute: Sept 2014 to Oct 2015
📅 Short termThe stock may see positive sentiment as a significant legal risk and potential financial liability have been cleared.
📈 Long termLimited structural impact on operations, but it reinforces the company's ability to defend its import-export valuation practices.
⚠ Risk flags
- Potential for the Customs Department to appeal the CESTAT order in a higher court
Key Highlights
CESTAT set aside a quantified demand of ₹15,24,30,536 (₹15.24 Cr) plus unquantified interest and penalties.
The litigation pertained to fish meal imports under the Advance Authorisation Scheme between September 2014 and October 2015.
The company is entitled to seek a refund of ₹75,00,000 (₹0.75 Cr) appropriated under the previous Order-in-Original.
The tribunal held that the Department failed to establish undervaluation with cogent evidence, making the demand unsustainable.
The total demand set aside represents approximately 3.4% of the company's current Net Worth of ₹447 Cr.
👀 What to Watch
Investors should monitor if the Customs Department chooses to appeal this tribunal order in a higher court. The immediate positive is the removal of a significant contingent liability from the balance sheet.
99.96% Approval: Mukka Proteins Shareholders Clear Preferential Issue of Convertible Warrants
Mukka Proteins has received overwhelming shareholder approval (99.96% in favor) for the issuance of warrants convertible into equity shares on a preferential basis. This procedural milestone allows the company to move forward with its planned capital infusion, which the company context indicates is approximately ₹98 Cr. The funds are earmarked for product diversification and supporting the acquisition of a 68% stake in United Gulf Fishery Products LLC in Oman. Given the company's high debt-to-equity ratio of 1.53, this equity-linked fundraise is a critical step for its expansion strategy.
Confidence: HIGH
What changedShareholders have officially authorized the company to issue convertible warrants on a preferential basis, moving the fundraise from a proposal to an approved corporate action.
Why it mattersThis approval facilitates a capital injection equivalent to approximately 12.5% of the company's current market cap, providing necessary liquidity for its ₹98 Cr expansion and diversification plans while potentially improving the balance sheet leverage.
Approval Percentage: 99.96%Total Votes in Favor: 22,01,79,675Planned Fundraise: ₹98 CrFundraise vs Market Cap: ~12.5%Debt-to-Equity Ratio: 1.53
📅 Short termThe successful passing of the resolution is likely to be viewed positively by the market as it clears the path for growth capital and strategic acquisitions.
📈 Long termThe long-term impact depends on the successful execution of the Oman acquisition and the ability of new products to improve the current operating profit margin of 7.9%.
⚠ Risk flags
- Equity dilution for existing shareholders upon conversion of warrants
- High debt levels (₹682 Cr) relative to net worth (₹447 Cr)
Key Highlights
99.96% of valid votes (22,01,79,675 votes) were cast in favor of the special resolution for warrant issuance.
Only 0.04% of votes (82,433) were cast against the proposal by non-institutional public shareholders.
The resolution is deemed approved as of July 12, 2026, following the conclusion of the remote e-voting period.
The fundraise supports a planned ₹98 Cr investment for product diversification and international expansion.
Promoter group participation was 100% in favor, representing 21,99,98,800 votes.
👀 What to Watch
Investors should monitor the upcoming board meeting for the formal allotment of warrants and the disclosure of the conversion price and specific allottees. Tracking the progress of the Oman acquisition and the utilization of these funds for diversification will be key to assessing long-term value creation.
₹47 Cr fundraise: Mukka Proteins issues corrigendum for 2 crore warrant issuance
Mukka Proteins has issued a corrigendum to its postal ballot notice for a proposed preferential issue of 2,00,00,000 convertible warrants. The company aims to raise ₹47 crore at an issue price of ₹23.50 per warrant, which is slightly above the SEBI-mandated floor price of ₹23.18. A significant portion of the proceeds, ₹35 crore (74.5%), is allocated for working capital, while ₹5 crore is earmarked for business expansion. The clarification follows observations from NSE and BSE regarding the objects of the issue and pricing methodology.
Confidence: HIGH
What changedThe company provided a detailed breakdown of the use of proceeds and clarified the pricing logic (VWAP vs. Independent Valuation) following regulatory queries from NSE and BSE.
Why it mattersThis filing ensures the ₹47 crore fundraise proceeds legally; the capital is essential for a company with a high Debt/Equity ratio of 1.53 and significant working capital needs in the fish meal industry.
Total Fundraise Value: ₹47 croreIssue Price per Warrant: ₹23.50Fundraise vs Market Cap: ~6.0%Working Capital Allocation: ₹35 croreSEBI Floor Price (90-day VWAP): ₹23.18
📅 Short termThe clarification resolves regulatory hurdles for the fundraise, likely leading to a neutral-to-stable stock reaction as the price is set near the current market price of ₹23.6.
📈 Long termWhile the fundraise supports growth initiatives like the Oman expansion, the primary use for working capital suggests ongoing liquidity management rather than aggressive new capacity creation.
⚠ Risk flags
- Equity dilution from 2 crore new shares
- High reliance on working capital (74% of issue)
- High existing Debt/Equity of 1.53
Key Highlights
Proposed issuance of 2,00,00,000 convertible warrants at ₹23.50 per warrant to raise ₹47 crore.
Allocation of ₹35 crore towards working capital requirements to support operations.
Issue price of ₹23.50 is higher than the SEBI floor price of ₹23.18 and the valuer's fair value of ₹18.14.
Funds to be utilized within a tentative timeline of 24 months from the date of receipt.
Warrants are convertible into equity shares within a maximum period of 18 months from allotment.
👀 What to Watch
Investors should monitor the outcome of the postal ballot ending July 12, 2026, and track the progress of the Oman acquisition which these funds may indirectly support.
₹7.55 Cr Tax Addition Sustained for Mukka Proteins; Partial Relief on ₹8.08 Cr
Mukka Proteins has received an appellate order for Assessment Year 2018-19, resulting in a mixed outcome. The Commissioner of Income Tax (Appeals) deleted additions worth ₹8.08 Cr (₹4.48 Cr in prior period income and ₹3.60 Cr in stock additions). However, an addition of ₹7.55 Cr related to alleged excess stock was sustained under Section 115BBE, which carries a high effective tax rate of 78%. Since the company has already paid tax at 34.94% on this amount, it faces a potential additional liability for the differential tax amount.
Confidence: HIGH
What changedA legacy tax dispute from AY 2018-19 has reached the first appellate stage, resulting in the company winning relief on approximately 52% of the disputed additions while losing on the remainder.
Why it mattersThe sustained addition of ₹7.55 Cr is subject to a punitive 78% tax rate; the potential additional tax liability (the delta between 78% and the 34.94% already paid) represents roughly 5.7% of the company's TTM PAT of ₹57 Cr.
Sustained Addition: ₹7.55 CrRelief Granted (Total): ₹8.08 CrSpecial Tax Rate (Sec 115BBE): 78%Sustained Addition vs TTM PAT: 13.2%
📅 Short termNeutral to slightly negative as the market weighs the benefit of the ₹8.08 Cr relief against the high-tax penalty on the sustained ₹7.55 Cr.
📈 Long termLimited; this is a legacy tax matter from 2018 and does not impact the company's current operational capacity or growth strategy in Oman.
⚠ Risk flags
- Potential additional tax outflow due to high effective tax rate under Section 115BBE
- Continued litigation risk
Key Highlights
Relief obtained through the deletion of ₹4.48 Cr addition related to prior period income.
Partial relief granted for stock additions, with ₹3.60 Cr deleted out of the original ₹11.15 Cr.
Addition of ₹7.54,55,608 for alleged excess stock sustained by the appellate authority.
Sustained addition is taxable at a special rate of 78% under Section 115BBE.
Company is currently evaluating further legal remedies to contest the sustained addition.
👀 What to Watch
Monitor whether the company files a further appeal with the Income Tax Appellate Tribunal (ITAT) to contest the sustained ₹7.55 Cr addition and its associated high tax rate.
Mukka Proteins Acquires 51% Stake in Delta Marine Products for Rs 11.10 Crore
Mukka Proteins Limited has successfully completed the acquisition of a 51% controlling stake in Delta Marine Products, a partnership firm, for a total cash consideration of Rs 11.10 crore. The target entity is engaged in the manufacturing of fish meal and fish oil, which is the core business of Mukka Proteins. Delta Marine Products showed significant revenue growth, with turnover rising from Rs 3.64 crore in FY24 to Rs 28.17 crore in FY25, although it reported a marginal net loss of Rs 19.73 lakhs in the latest fiscal year. This strategic move is intended to expand production capacity and improve market reach through operational optimization.
Key Highlights
Acquired 51% controlling stake in Delta Marine Products for a cash consideration of Rs 11.10 crore.
Target entity's turnover increased by over 670% year-on-year to Rs 28.17 crore in FY 2024-25.
The acquisition aligns with Mukka's core business of fish meal and fish oil manufacturing to drive capacity expansion.
The transaction was completed on June 25, 2026, through capital contribution rather than a share swap.
Target entity reported a net loss of Rs 19.73 lakhs in FY25, indicating a focus on turnaround through operational synergies.
👀 What to Watch
Investors should view this as a strategic expansion move that adds significant top-line potential; however, they should monitor the company's ability to turn the target entity profitable through operational efficiencies.
Mukka Proteins to raise ₹47 Crore via preferential issue of 2 Crore convertible warrants
Mukka Proteins Limited has applied for in-principle approval from BSE and NSE to issue 2,00,00,000 convertible warrants on a preferential basis. The warrants are priced at ₹23.50 each, aiming to raise a total of ₹47 crore from 15 non-promoter investors. These warrants will be convertible into equity shares ranking pari-passu with existing shares. The issue is subject to shareholder and regulatory approvals, with the relevant date fixed as June 12, 2026.
Key Highlights
Proposed issuance of 2,00,00,000 convertible warrants at an issue price of ₹23.50 per warrant.
Total capital infusion of ₹47,00,00,000 (₹47 Crore) through the preferential route.
Allottees consist entirely of non-promoter investors, including individuals and entities like Multiplex Capital Limited.
The issue price was determined based on a valuation report from an Independent Registered Valuer.
Post-issue, no individual allottee will exceed 5% of the company's fully diluted share capital.
👀 What to Watch
Investors should track the upcoming shareholder meeting for approval and monitor how the company intends to utilize the ₹47 crore for growth. The issue price of ₹23.50 provides a significant valuation benchmark for the stock.
Mukka Proteins to raise ₹47 crore through issuance of 2 crore convertible warrants
Mukka Proteins Limited has issued a postal ballot notice to seek shareholder approval for a preferential issue of up to 2,00,00,000 convertible warrants. The warrants are priced at ₹23.50 each, aiming to raise a total of ₹47 crore from 15 non-promoter investors. Each warrant is convertible into one equity share of face value ₹1 within 18 months from the date of allotment. The e-voting period for this special resolution is scheduled from June 13, 2026, to July 12, 2026.
Key Highlights
Proposed issuance of 2,00,00,000 convertible warrants at an issue price of ₹23.50 per warrant.
Total fundraise size is capped at ₹47,00,00,000 (₹47 crore) targeting 15 non-promoter entities.
Warrants are convertible into equity shares at a premium of ₹22.50 per share within 18 months.
The relevant date for floor price determination is fixed as June 12, 2026.
Remote e-voting for shareholders concludes on July 12, 2026, with results expected within two working days.
👀 What to Watch
Investors should monitor the final approval of the resolution and the subsequent conversion of warrants, as it will lead to equity dilution but provides growth capital for the company.
Mukka Proteins to Acquire 51% Stake in Delta Marine Products for Rs 11.10 Crore
Mukka Proteins Limited has approved a strategic investment to acquire a 51% controlling stake in Delta Marine Products, a partnership firm engaged in manufacturing fish meal and fish oil. The acquisition will cost up to Rs 11.10 crore, to be paid in cash through capital contributions in one or more tranches. While the target entity reported a significant turnover of Rs 28.17 crore in FY 2024-25, it recorded a net loss of Rs 19.73 lakhs. The transaction is expected to be completed by September 30, 2026, aiming to enhance Mukka's production capacity and market reach.
Key Highlights
Acquisition of a 51% majority stake in Delta Marine Products for a consideration not exceeding Rs 11.10 crore.
Target entity's turnover surged from Rs 3.64 crore in FY24 to Rs 28.17 crore in FY25, showing rapid scale-up.
The deal is a strategic horizontal integration as both entities operate in the fish meal and fish oil industry.
The acquisition is expected to be finalized by September 30, 2026, via cash-based capital contributions.
Delta Marine Products reported a PAT loss of Rs 19.73 lakhs for FY 2024-25, which Mukka aims to improve through operational optimization.
👀 What to Watch
Investors should view this as a growth-oriented move that expands Mukka's core capacity, though they should monitor the company's ability to turn the target entity profitable. The rapid revenue growth of Delta Marine suggests strong market demand for its products.
Mukka Proteins to Acquire 51% Stake in Aqua Marine for Rs 15 Crore
Mukka Proteins Limited has approved a strategic investment to acquire a 51% controlling stake in Aqua Marine, a partnership firm involved in manufacturing fish meal and fish oil. The acquisition will cost up to Rs 15 crore, to be paid in cash via capital contributions in one or more tranches. Aqua Marine reported a turnover of Rs 32.15 crore for FY 2024-25, which is a significant drop from its FY 2023-24 turnover of Rs 54.67 crore. The deal is expected to be completed by September 30, 2026, and aims to expand Mukka's production capacity and market reach.
Key Highlights
Acquisition of 51% stake in Aqua Marine for a total consideration not exceeding Rs 15 crore.
Target entity is in the same line of business (fish meal and fish oil), facilitating vertical integration.
Aqua Marine's FY25 turnover was Rs 32.15 crore with a PAT of approximately Rs 10.68 lakhs.
The investment will be made in cash through capital contributions in tranches by September 30, 2026.
Strategic move intended to optimize operational processes and expand core business capacity.
👀 What to Watch
Investors should view this as a strategic expansion move, though they should monitor the target's declining turnover and low profitability margins to ensure the acquisition becomes accretive.
Mukka Proteins to Raise ₹47 Cr via Warrants and Acquire 51% Stake in Two Firms for ₹26.1 Cr
Mukka Proteins Limited has approved a preferential issue of 2,00,00,000 fully convertible warrants at ₹23.50 per warrant, aiming to raise ₹47 crore from non-promoter investors. The company is simultaneously deploying capital to acquire 51% stakes in two partnership firms, Delta Marine Products and Aqua Marine, for ₹11.10 crore and ₹15 crore respectively. These strategic investments are focused on expanding the company's core fish meal and fish oil business and optimizing production efficiency. The warrants are convertible into equity shares within 18 months, which will eventually increase the company's paid-up equity capital to ₹32 crore.
Key Highlights
Approved issuance of 2 crore fully convertible warrants at ₹23.50 each, aggregating to ₹47 crore.
Acquiring 51% controlling stake in Delta Marine Products for a consideration up to ₹11.10 crore.
Acquiring 51% controlling stake in Aqua Marine for a consideration up to ₹15.00 crore.
Target entities Delta Marine and Aqua Marine reported FY25 turnovers of ₹28.17 crore and ₹32.15 crore respectively.
The acquisitions are expected to be completed by September 30, 2026, to drive capacity expansion.
👀 What to Watch
Investors should view this as a growth-oriented move that expands the company's manufacturing footprint; however, they should monitor the post-acquisition integration and the impact on consolidated profitability.
Mukka Proteins to raise ₹47 Cr via Warrants; acquires 51% stake in two firms for ₹26.1 Cr
Mukka Proteins has approved raising ₹47 crore through the issuance of 2 crore convertible warrants to non-promoter investors at ₹23.50 per warrant. The company is also aggressively expanding by acquiring a 51% stake in two fish meal manufacturing firms, Delta Marine Products and Aqua Marine, for a combined investment of up to ₹26.1 crore. These strategic moves are intended to enhance production capacity and market reach, with the acquisitions slated for completion by September 30, 2026. The warrants are convertible into equity shares within 18 months, which will eventually increase the company's paid-up capital to ₹32 crore.
Key Highlights
Approved issuance of 2,00,00,000 fully convertible warrants at ₹23.50 each to raise ₹47 crore.
Acquiring 51% stake in Delta Marine Products for up to ₹11.10 crore (FY25 Turnover: ₹28.17 Cr).
Acquiring 51% stake in Aqua Marine for up to ₹15 crore (FY25 Turnover: ₹32.15 Cr).
Warrants are convertible into equity shares within 18 months at a premium of ₹22.50 per share.
The investments are aimed at capacity expansion and optimization of operational processes in the core fish meal business.
👀 What to Watch
The capital infusion and strategic acquisitions indicate a strong growth trajectory; investors should monitor the successful integration of these firms and their impact on consolidated margins.
